Outcome of Board Meeting

Ref: 11/SE/LC/2026-27 Date: November 05, 2026 To, To, National Stock Exchange of India Limited BSE Limited (“BSE”) (“NSE”) Listing Department Listing Department Corporate Relationship Department Exchange Plaza, C-1 Block G, Bandra Kurla Phiroze Jeejeebhoy Towers, Complex Bandra (East), Mumbai – 400051 Dalal Street, Fort, Mumbai - 400 001 NSE Scrip Symbol: SMT BSE Scrip Code: 545001 ISIN: INE356Y01018 ISIN: INE356Y01018 Subject: Outcome of Board Meeting, pursuant to Regulation 30 read with Regulation 33 and other applicable provisions of SEBI (Listing Obligations and Disclosure Requirements Regulations, 2015 (“Listing Regulations”). Dear Sir/Madam, Pursuant to Regulation 30 and Regulation 33 read with Schedule III and other applicable provisions of the Listing Regulations, we would like to inform you that, the Board of Directors of the Sahajanand Medical Technologies Limited (“Company”), at its meeting held today, i.e., November 05, 2026, have inter-alia considered, approved the following business: 1. The Unaudited Standalone and Consolidated Financial Results along with Limited Review Report for Quarter and Half -year ended September 30, 2026 are enclosed herewith. 2. Investment by Sahajanand Medical Technologies Ireland Limited, Wholly Owned Subsidiary of the Company in SNP Medical Corp., a US based corporation registered in Delaware. Details as required under Listing Regulations read with SEBI Circular No. HO/49/14/14(7)2025-CFD- POD2/I/3762/2026 dated January 30, 2026, (“SEBI Circular”) are enclosed herewith as Annexure A 3. Appointment of M/s Amit Jaste & Associates, Company Secretaries (CP. No. 12234) as the Secretarial Auditor of the Company for the term of five consecutive financial years commencing from FY 2026-27 to FY 2030-31, subject to the approval of shareholders of the Company. Details as required under Listing Regulations read with SEBI Circular are enclosed herewith as Annexure B The meeting commenced at 3:00 PM (IST) and concluded at 4:43 PM (IST). The above intimation is also available on the website of the Company at www.smtpl.com and on the website of BSE Limited and National Stock Exchange of India Limited. Kindly take the same on records. Thanking you, For Sahajanand Medical Technologies Limited Bhargav Dhirajlal Kotadia Managing Director & Chief Executive Officer DIN: 06575042 Deloitte CharteredAccountants OneInternationalCenter, Haskins & SellsLLP Tower3,31stFloor, SenapatiBapatMarg ElphinstoneRoad(West) Mumbai-400013 Maharashtra,India Tel:+912261856000 Fax:+912261854101 INDEPENDENTAUDITOR’SREVIEWREPORTONREVIEWOFINTERIMCONSOLIDATEDFINANCIALRESULTS TOTHEBOARDOFDIRECTORSOFSahajanandMedicalTechnologiesLimited 1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of Sahajanand MedicalTechnologiesLimited(“theParent”) anditssubsidiaries(theParentanditssubsidiariestogetherreferred toas“theGroup”), forthequarterandsixmonthsendedSeptember30,2026(“theStatement”)beingsubmittedby the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements)Regulations,2015,asamended("theListingRegulations”). 2. This Statement, which is the responsibility of the Parent’s Management and approved by the Parent’s Board of Directors,hasbeenpreparedinaccordancewiththerecognitionandmeasurementprincipleslaiddownintheIndian AccountingStandard34“InterimFinancialReporting”(“IndAS34”),prescribedunderSection133oftheCompanies Act,2013readwithrelevantrulesissuedthereunderandotheraccountingprinciplesgenerallyacceptedinIndiaand in compliance with Regulation 33of the ListingRegulations. Our responsibilityis to express a conclusion on the Statementbasedonourreview. 3. Weconductedourreview of theStatementinaccordancewiththeStandardonReviewEngagements(SRE) 2410 “ReviewofInterimFinancialInformationPerformedbytheIndependentAuditoroftheEntity”,issuedbytheInstitute of Chartered Accountants of India (ICAI). A review of interim financialinformation consists of makinginquiries, primarilyof Parent’spersonnelresponsibleforfinancialandaccountingmatters,andapplyinganalyticalandother reviewprocedures. AreviewissubstantiallylessinscopethananauditconductedinaccordancewithStandardson AuditingspecifiedunderSection143(10)oftheCompaniesAct,2013andconsequentlydoesnotenableustoobtain assurancethatwewouldbecomeawareofallsignificantmattersthatmightbeidentifiedinanaudit.Accordingly,we donotexpressanauditopinion. WealsoperformedproceduresinaccordancewiththecircularissuedbytheSEBIunderRegulation33(8)oftheSEBI (ListingObligationsandDisclosureRequirements)Regulations,2015,asamended,totheextentapplicable. 4. TheStatementincludestheresultsofthefollowingentitieslistedinAnnexureA. 5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of other auditors referred to in paragraph 6 below, nothinghas come to our attentionthatcausesustobelievethattheaccompanyingStatement,preparedinaccordancewiththerecognition andmeasurementprincipleslaiddownintheaforesaidIndianAccountingStandardandotheraccountingprinciples generallyacceptedinIndia,hasnotdisclosedtheinformationrequiredtobedisclosedintermsofRegulation33of the SEBI(ListingObligationsandDisclosureRequirements)Regulations,2015,asamended,includingthemannerin whichitistobedisclosed,orthatitcontainsanymaterialmisstatement. 6. We did not review the interim financialresultsof 6 subsidiaries includedin the consolidated unaudited financial results,whoseinterimfinancialresultsreflecttotalassetsofRs.21,098.46lakhsasatSeptember30,2026andtotal revenuesofRs.8,564.62lakhsandRs.14,838.02lakhsforthequarterandsixmonthsendedSeptember30,2026, totalnet profit/(loss) after tax of Rs. 683.32 lakhs and Rs. (346.24) lakhs for the quarter and six months ended September 30, 2026 and totalcomprehensive income/ (loss) of Rs. 683.32 lakhs and Rs. (346.24) lakhs for the quarterandsixmonthsendedSeptember30,2026respectivelyandnetcashinflow ofRs.28.35lakhsforthesix months ended September 30, 2026, as considered in the Statement. These interim financial results have been reviewedbyotherauditorswhosereportshavebeenfurnishedtousbytheManagementandourconclusiononthe Regd.OrSta^QneInternationalCenter,Tower3,31stfloor,SenapatiBapatMarg,ElphinstoneRoad(West),Mumbai-400013,Maharashtra,India. DeloitteHaskinMLSellsLLPisregisteredwithLimitedLiabilityhavingLLPidentificationNo:AAB-8737 Deloitte Haskins & Sells LLP Statement, in so far as it retates to the amounts and discLosures included in respect of these subsidiaries is based sotety on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above. Our conctusion on the Statement is not modifled in resoect of these matters. For Detoitte Haskins & Setts LLP Chartered Accountants Firm Registration No. 1 17366\,11l'!V- 1 0001 B Terence Lewis Partner Membership No. '107502 trq3 26to7 5o2T2-\<€KO Place: Mumbai Date: November 05,2026 Deloitte Haskins & SellsLLP Annexure A: Sr. No. Name of the Entities: Parent ,] Sahajanand Medical Technotogies Limited Subsidiaries 2 SMT Cardiovascutar Private Limited 3 Sahajanand MedicalTechnologles lreLand Limited 4 Vascutar lnnovation Compa nV Limited 5 SMT Germa ny Gmbh 6 Sahajanand MedicatTechnotogies lberia SL / SMT lmportadora E Distribuidora De Produtos HospitaLares Ltda. Sl"1T Switzertand AG 9 SMT Potonia sp. Z o.o. 10 SMT CIS LLC 11 SMT France SAS 12 SMT USA Ltd 13 SMT Austratia PTY Ltd (w.e.f. Aprlt 01 , 2026) ')t l" Sahljanxnd M€dicol Technologica Limited RBisrcnd ofli@ sahjinand Es c. v.krmrimidi. Ner Dibl'ori. vcd Roid. sunr :re5 00.r. cL'jinr. tndr clNr u]1ll9Gl200lPLc010t2t. Enr{it: tn\ 610^ 3ft1fl$ ? snr f. wcbs Umudltcd Consrid.rd Sr{.ftcnr or Piofit ond lrr ao. r[r qrrd.rrid5k mdirh rtrdcd 30 tul,lcmbcr,1016 Chan36 in inrqlo 6 oIfinnicd so.d., nek in.rnde aM \q*-in.phsrc$ Dcp@i.rion aid amniston c$cn* r.r rcrar.d u iq pc'iod,lq, Orhrcom0Ehen.n! In.ono Ir.tu rhr. sirr nor hc Nlturln.d rub&qlc ty [Showing first 8,000 characters — download PDF for full document]